SecBot SecBot
8-K ·Filed Apr 24, 2026

HCA

HCA Healthcare, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0001193125-26-174933
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Results were in line with expectations, and guidance was reaffirmed. The stock is likely to trade range-bound near-term. Monitor upcoming quarters for execution on volume recovery and margin trends.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$432.55
T+0 close · Apr 24, 2026 · via day close
Latest settled
−14.36%
T+60 · $370.42
Vs SPY
−18.31%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 24 $432.55entry
  2. T+1 · 7mo ago +3.04%α +2.88% · $445.70
  3. T+5 · 7mo ago +0.44%α −0.47% · $434.45
  4. T+20 · 6mo ago −9.25%α −13.27% · $392.56
  5. T+60 · 4mo ago −14.36%α −18.31% · $370.42
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

HCA Healthcare reported Q1 2026 results with revenue of $19.109 billion (4.3% YoY growth) and diluted EPS of $7.15, matching consensus. The company reaffirmed its full-year 2026 guidance and repurchased $1.571 billion in shares. Despite lower respiratory volumes, Medicaid supplemental program recognition offset impacts.

Key Financial Metrics

EPS
$7.15
est $7.15 · 0.0%
Revenue
$19.1B
est $19.1B · +0.2% · +4.3% YoY
Rating
in line
Guidance
$76.500 to $80.000 billion
maintained

Key Facts

  • Q1 2026 revenue was $19.109 billion, up 4.3% YoY
  • Diluted EPS was $7.15, up 10.9% YoY and in line with consensus of $7.15
  • Adjusted EBITDA increased 1.9% to $3.802 billion
  • Company reaffirmed 2026 full-year guidance: EPS $29.10–$31.50, revenue $76.5–80.0 billion
  • Repurchased 3.157 million shares for $1.571 billion during Q1
  • Declared quarterly dividend of $0.78 per share

Financial Impact

Revenue increased 4.3% YoY to $19.109 billion; EPS of $7.15 matched consensus

revenueepsebitdashare_count

Risk Factors

  • Lower-than-expected patient volumes due to reduced respiratory activity
  • Dependence on Medicaid supplemental payments for financial performance

Market Snapshot

Exchange
NYSE
Sector
Services-General Medical & Surgical Hospitals, NEC

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-174933
Document: hca-20260424.htm0001193125-26-174933
Document: 0001193125-26-174933-index-headers.html0001193125-26-174933
Document: 0001193125-26-174933-index.html0001193125-26-174933
Document: 0001193125-26-174933.txt0001193125-26-174933
8-K Data (Synthetic)0001193125-26-174933

US Market Status

Market Closed · Opens in 7h 43m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 24, 2026